Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Bristol Myers Drug Patent Portfolio

Bristol Myers owns 17 orange book drugs protected by 141 US patents with Baraclude having the least patent protection, holding only 2 patents. And Abraxane with maximum patent protection, holding 32 patents. Given below is the list of Bristol Myers's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10925832 Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
Active
US10933020 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
Active
US11452692 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
Active
US11471413 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
Active
US11890378 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
Active
US11400092 Methods of treating myeloproliferative disorders 24 Sep, 2039
Active
US9732062 Therapeutically active compounds and their methods of use 16 Sep, 2034
Active
US10093654 Therapeutically active compounds and their methods of use 01 Aug, 2034
Active
US9738625 Therapeutically active compounds and their methods of use 01 Aug, 2034
Active
US9511046 Methods of treating pancreatic cancer 12 Jul, 2034
Active
US9511046 Methods of treating pancreatic cancer 12 Jan, 2034
Active
US10294215 Therapeutically active compounds and their methods of use 07 Jan, 2033
Active
US9512107 Therapeutically active compositions and their methods of use 07 Jan, 2033
Active
US9393318 Methods of treating cancer 04 Sep, 2032
Active
US9597409 Methods of treating cancer 04 Sep, 2032
Active
US10391094 Compositions and methods for treating myelofibrosis 04 Jun, 2032
Active
US9393318 Methods of treating cancer 04 Mar, 2032
Active
US9597409 Methods of treating cancer 04 Mar, 2032
Active
US7528143 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Nov, 2031
Active
US9326945 Apixaban formulations 24 Aug, 2031
Active
US8629171 Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt 13 Jun, 2031
Active
US9326945 Apixaban formulations 24 Feb, 2031
Active
US10238643 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
Active
US10265311 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
Active
US10369143 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
Active
US10369144 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
Active
US10695339 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
Active
US8329159 Hepatitis C virus inhibitors 24 Jul, 2029
Active
US8138199 Use of bi-aryl meta-pyrimidine inhibitors of kinases 30 Jun, 2028
Active
US8741929 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas 08 Mar, 2028
Active
US8642025 Hepatitis C virus inhibitors 11 Aug, 2027
Active
US8900566 Hepatitis C virus inhibitors 08 Aug, 2027
Active
US9421192 Hepatitis C virus inhibitors 08 Aug, 2027
Active
US6967208 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors 21 May, 2027
Active
US7465800 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 27 Apr, 2027
Active
US8034375 Combinations and modes of administration of therapeutic agents and combination therapy 13 Feb, 2027
Active
US7825246 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Dec, 2026
Active
US6967208 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors 21 Nov, 2026
Active
US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Sep, 2026
Active
US7758891 Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
Active
US8268348 Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
Active
US9101543 Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
Active
US8034375 Combinations and modes of administration of therapeutic agents and combination therapy 13 Aug, 2026
Active
US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Mar, 2026
Active
US7758891 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
Active
US8268348 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
Active
US9101543 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
Active
US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Aug, 2025 Expired
US7820788 Compositions and methods of delivery of pharmacological agents 27 Apr, 2025 Expired
US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Feb, 2025 Expired
US7855217 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 24 Nov, 2024 Expired
US7820788 Compositions and methods of delivery of pharmacological agents 27 Oct, 2024 Expired
US7923536 Compositions and methods of delivery of pharmacological agents 09 Jun, 2024 Expired
US8138229 Compositions and methods of delivery of pharmacological agents 09 Jun, 2024 Expired
US8314156 Compositions and methods of delivery of pharmacological agents 09 Jun, 2024 Expired
US7923536 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023 Expired
US8138229 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023 Expired
US8314156 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023 Expired
US7230012 Pharmaceutical compositions and dosage forms of thalidomide 09 Dec, 2023 Expired
US7468363 Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023 Expired
US7968569 Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023 Expired
US8492406 Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023 Expired
US7135465 Sustained release beadlets containing stavudine 18 Aug, 2023 Expired
US8530498 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione 15 May, 2023 Expired
US8648095 Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor 15 May, 2023 Expired
US9101621 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation 15 May, 2023 Expired
US9101622 Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone 15 May, 2023 Expired
US9155730 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023 Expired
US9393238 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023 Expired
US7189740 Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes 11 Apr, 2023 Expired
US8404717 Methods of treating myelodysplastic syndromes using lenalidomide 11 Apr, 2023 Expired
US9056120 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine 11 Apr, 2023 Expired
US7135465 Sustained release beadlets containing stavudine 18 Feb, 2023 Expired
US7608280 Method of producing FR901228 22 Aug, 2021 Expired
US7611724 Method of producing FR901228 22 Aug, 2021 Expired
US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Apr, 2021 Expired
US6596746 Cyclic protein tyrosine kinase inhibitors 28 Dec, 2020 Expired
US7153856 Cyclic protein tyrosine kinase inhibitors 28 Oct, 2020 Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020 Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6869399 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US7141018 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US7959566 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US7125875 Cyclic protein tyrosine kinase inhibitors 13 Oct, 2020 Expired
US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Oct, 2020 Expired
US6596746 Cyclic protein tyrosine kinase inhibitors 28 Jun, 2020 Expired
US7153856 Cyclic protein tyrosine kinase inhibitors 28 Apr, 2020 Expired
US7125875 Cyclic protein tyrosine kinase inhibitors 13 Apr, 2020 Expired
US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jan, 2020 Expired
US6413980 Nitrogen containing heterobicycles as factor Xa inhibitors 22 Dec, 2019 Expired
US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019 Expired
US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019 Expired
US5635517 Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines 04 Oct, 2019 Expired
US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jul, 2019 Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Jun, 2019 Expired
US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019 Expired
US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019 Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Dec, 2018 Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US7874984 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Aug, 2018 Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jul, 2018 Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Feb, 2018 Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jan, 2018 Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Dec, 2017 Expired
US7435745 Methods and compositions for inhibition of angiogenesis 03 Nov, 2017 Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Jun, 2017 Expired
USRE41884 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions 14 Aug, 2016 Expired
US6281230 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016 Expired
US6555554 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016 Expired
US7119106 Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline 24 Jul, 2016 Expired
US8288415 Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione 24 Jul, 2016 Expired
US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Aug, 2015 Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Mar, 2015 Expired
US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Feb, 2015 Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Oct, 2014 Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Sep, 2014 Expired
US5629327 Methods and compositions for inhibition of angiogenesis 13 May, 2014 Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Apr, 2014 Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 Nov, 2013 Expired
US4977138 FR901228 substance and preparation thereof 22 Aug, 2013 Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 May, 2013 Expired
US5498421 Composition useful for in vivo delivery of biologics and methods employing same 12 Mar, 2013 Expired
US6235756 Methods and compositions for inhibition of angiogenesis by thalidomide 01 Mar, 2013 Expired
US7723361 Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide 01 Mar, 2013 Expired
US8143283 Methods for treating blood-born tumors with thalidomide 01 Mar, 2013 Expired
US5439686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor 22 Feb, 2013 Expired
US6096331 Methods and compositions useful for administration of chemotherapeutic agents 22 Feb, 2013 Expired
US6506405 Methods and formulations of cremophor-free taxanes 22 Feb, 2013 Expired
US6537579 Compositions and methods for administration of pharmacologically active compounds 22 Feb, 2013 Expired
US6749868 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 22 Feb, 2013 Expired
US6753006 Paclitaxel-containing formulations 22 Feb, 2013 Expired
US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase 07 Aug, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Bristol Myers.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed
Critical
08 Jul, 2024 US8314156 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9511046
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9512107
Maintenance Fee Reminder Mailed
Critical
11 Mar, 2024 US9393238
Payment of Maintenance Fee, 12th Year, Large Entity 06 Mar, 2024 US8268348 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 03 Jan, 2024 US9393318
Payment of Maintenance Fee, 8th Year, Large Entity 18 Oct, 2023 US9326945 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 09 Oct, 2023 US10610125
Payment of Maintenance Fee, 12th Year, Large Entity 06 Sep, 2023 US8138199
Payment of Maintenance Fee, 12th Year, Large Entity 06 Sep, 2023 US8138229 (Litigated)
Expire Patent
Critical
17 Jul, 2023 US7959566
Patent Term Extension Certificate
Critical
25 May, 2023 US7528143
Payment of Maintenance Fee, 8th Year, Large Entity 29 Mar, 2023 US9155730
Payment of Maintenance Fee, 12th Year, Large Entity 29 Mar, 2023 US8034375
Withdrawal of Application for PTE
Critical
27 Feb, 2023 US7825246


Bristol Myers's Drug Patent Litigations

Bristol Myers's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 23, 2010, against patent number US8329159. The petitioner , challenged the validity of this patent, with Makonen Belema et al as the respondent. Click below to track the latest information on how companies are challenging Bristol Myers's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10610125 August, 2022 Terminated-Settled
(06 Jan, 2023)
Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.
US7968569 September, 2018 Terminated-Denied
(14 Mar, 2019)
Celgene Corporation Alvogen Pine Brook LLC
US7968569 September, 2018 Institution Denied
(14 Mar, 2019)
Celgene Corporation Alvogen Pine Brook LLC et al.
US8404717 August, 2018 Institution Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc et al.
US7189740 August, 2018 Institution Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc. et al.
US7189740 August, 2018 Terminated-Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc.
US9056120 August, 2018 Institution Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc. et al.
US9056120 August, 2018 Terminated-Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc.
US8404717 August, 2018 Terminated-Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc
US9326945 April, 2018 Terminated-Settled
(16 Jan, 2019)
Pfizer Inc. Mylan Pharmaceuticals Inc.
US8741929 February, 2018 Terminated-Denied
(27 Sep, 2018)
Celgene Corporation Apotex Inc.
US8741929 February, 2018 Institution Denied
(27 Sep, 2018)
Celgene Corporation Apotex Inc. et al.
US7820788 November, 2017 Terminated-Settled
(13 Jul, 2018)
Abraxis BioScience, LLC Apotex Inc.
US8138229 November, 2017 Terminated
(13 Jul, 2018)
Abraxis BioScience, LLC et al. Apotex Inc. et al.
US7923536 November, 2017 Terminated-Settled
(13 Jul, 2018)
Abraxis Biosciences, LLC Apotex Inc.
US7820788 November, 2017 Terminated-Denied
(08 May, 2018)
Abraxis Biosciences, LLC Cipla Ltd.
US7923536 April, 2017 Terminated-Settled
(08 May, 2018)
ABRAXIS BIOSCIENCE, LLC Actavis LLC
US7820788 November, 2017 Institution Denied
(08 May, 2018)
Abraxis Biosciences, LLC et al. Cipla Ltd. et al.
US8138229 November, 2017 Terminated-Denied
(08 May, 2018)
AbraxisBiosciences, LLC Cipla Ltd.
US8138229 November, 2017 Institution Denied
(08 May, 2018)
AbraxisBiosciences, LLC et al. Cipla Ltd. et al.
US7923536 November, 2017 Institution Denied
(08 May, 2018)
Abraxis Biosciences, LLC et al. Cipla Ltd. et al.
US7820788 April, 2017 Terminated-Settled
(08 May, 2018)
ABRAXIS BIOSCIENCE, LLC Actavis LLC
US8138229 April, 2017 Terminated-Settled
(08 May, 2018)
ABRAXIS BIOSCIENCE, LLC, Actavis LLC
US7923536 November, 2017 Terminated-Denied
(08 May, 2018)
Abraxis Biosciences, LLC Cipla Ltd.
US8853260 April, 2017 Terminated-Denied
(11 Oct, 2017)
ABRAXIS BIOSCIENCE, LLC Actavis LLC
US8853260 April, 2017 Institution Denied
(11 Oct, 2017)
ABRAXIS BIOSCIENCE, LLC et al. Actavis LLC
US6045501 April, 2015 Final Written Decision
(26 Oct, 2016)
Celgene Corporation Coalition For Affordable Drugs VI LLC
US6315720 April, 2015 Final Written Decision
(26 Oct, 2016)
Celgene Corporation Coalition for Affordable Drugs VI LLC
US6315720 April, 2015 FWD Entered
(26 Oct, 2016)
Celgene Corporation Coalition for Affordable Drugs VI LLC
US6967208 August, 2015 Institution Denied
(22 Feb, 2016)
Bristol-Myers Squibb Company Coalition for Affordable Drugs IX, LLC et al.
US6967208 August, 2015 Terminated-Denied
(22 Feb, 2016)
Bristol-Myers Squibb Company Coalition for Affordable Drugs IX, LLC
US5635517 May, 2015 Institution Denied
(16 Nov, 2015)
Celgene Corporation Coalition for Affordable Drugs VI LLC
US5635517 May, 2015 Terminated-Denied
(16 Nov, 2015)
Celgene Corporation Coalition for Affordable Drugs VI LLC
US8329159 August, 2010 Decision
(31 Jan, 2011)
Makonen Belema et al


Bristol Myers Drug Patents' Oppositions Filed in EPO

Bristol Myers drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 29, 2010, by Apotex Inc.. This opposition was filed on patent number EP05722772A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14737791A Feb, 2022 Accord Healthcare Revoked
EP14737791A Feb, 2022 Teva Pharmaceutical Industries Ltd. Revoked
EP14737791A Jan, 2022 Generics [UK] Limited Revoked
EP17175864A Aug, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP17175864A Aug, 2020 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP17175864A Aug, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17175864A Aug, 2020 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP17175864A Aug, 2020 Wittkopp, Alexander Granted and Under Opposition
EP17175864A Aug, 2020 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP17175864A Aug, 2020 von Seebach, Malte Granted and Under Opposition
EP17175864A Aug, 2020 Kutzenberger Wolff & Partner Granted and Under Opposition
EP17175864A Aug, 2020 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP17175864A Aug, 2020 Zentiva k.s. Granted and Under Opposition
EP17175864A Aug, 2020 Krka, d.d., Novo mesto Granted and Under Opposition
EP17175864A Aug, 2020 SANDOZ AG Granted and Under Opposition
EP17178613A Jul, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17175788A Jul, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP17175788A Jul, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17178613A Jul, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP17178613A Jul, 2020 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP17178613A Jul, 2020 KRKA, d.d., Novo mesto Granted and Under Opposition
EP17175788A Jul, 2020 Sandoz AG Granted and Under Opposition
EP17175788A Jul, 2020 KRKA, d.d., Novo mesto Granted and Under Opposition
EP17175788A Jul, 2020 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP17178613A Jul, 2020 Sandoz AG Granted and Under Opposition
EP17178613A Jul, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP17175788A Jul, 2020 Medichem S.A. Granted and Under Opposition
EP17175788A Jul, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP17178613A Jul, 2020 Medichem S.A. Granted and Under Opposition
EP17175788A Jul, 2020 Kutzenberger Wolff & Partner Granted and Under Opposition
EP17178613A Jul, 2020 Kutzenberger Wolff & Partner Granted and Under Opposition
EP17178613A Jul, 2020 Zentiva k.s. Granted and Under Opposition
EP17175788A Jul, 2020 Zentiva k.s. Granted and Under Opposition
EP17178613A Jul, 2020 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP17175788A Jul, 2020 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP17165979A Apr, 2020 Generics (UK) Ltd Revoked
EP17165979A Apr, 2020 Teva Pharmaceutical Industries Ltd Revoked
EP15190823A Sep, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP15190823A Sep, 2019 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP15190823A Sep, 2019 Zentiva, k.s. Granted and Under Opposition
EP15190823A Sep, 2019 Generics (U.K.) Limited Granted and Under Opposition
EP15190823A Sep, 2019 KRKA, d.d., Novo mesto Granted and Under Opposition
EP15190823A Sep, 2019 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP15190823A Aug, 2019 Hamm&Wittkopp Patentanwälte PartmbB Granted and Under Opposition
EP15190823A Aug, 2019 Sandoz AG Granted and Under Opposition
EP15190823A Aug, 2019 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP15199526A Aug, 2019 Generics [UK] Ltd Revoked
EP15199540A Aug, 2019 Generics (UK) Ltd Revoked
EP15199521A Aug, 2019 Hamm&Wittkopp Patentanwälte PartmbB Revoked
EP15199521A Aug, 2019 Bachelin, Martin, Dr. Revoked
EP15199521A Aug, 2019 Generics [UK] Ltd Revoked
EP15199521A Jul, 2019 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Revoked
EP15199521A Jul, 2019 Pruß, Timo Revoked
EP03799876A Mar, 2019 Teva Pharmaceutical Industries Ltd Revoked
EP03799876A Mar, 2019 Wittkopp, Alexander Revoked
EP11763292A Jun, 2017 Generics (UK) Ltd Revoked
EP11763292A Jun, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP11707284A Sep, 2016 Zentiva k.s. Revoked
EP11707284A Sep, 2016 LEK Pharmaceuticals d.d. Revoked
EP11707284A Sep, 2016 Intas Pharmaceuticals Ltd. Revoked
EP11707284A Sep, 2016 Hamm&Wittkopp Patentanwälte PartmbB Revoked
EP11707284A Sep, 2016 Generics (U.K.) Limited Revoked
EP11707284A Sep, 2016 Galenicum Health S.L. Revoked
EP11707284A Sep, 2016 KRKA, d.d., Novo mesto Revoked
EP11707284A Sep, 2016 STADA Arzneimittel AG Revoked
EP11707284A Sep, 2016 Plougmann Vingtoft a/s Revoked
EP11707284A Sep, 2016 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Revoked
EP11707284A Sep, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP09008756A Jul, 2015 Accord Healthcare Ltd Revoked
EP09008756A Jul, 2015 Generics [UK] Limited (trading as Mylan) Revoked
EP09008756A Jul, 2015 Hexal AG Revoked
EP09008756A Jul, 2015 Intellectual Property Services Revoked
EP09008756A Jul, 2015 Synthon B.V. Revoked
EP09008756A Jul, 2015 Actavis Group PTC EHF Revoked
EP06735710A Aug, 2012 MediGene Aktiengesellschaft Revoked
EP04783095A Aug, 2012 Teva Pharmaceutical Industries Ltd. Revoked
EP06735710A Aug, 2012 Generics [UK] Limited Revoked
EP04783095A Aug, 2012 Generics [UK] Limited Revoked
EP03728969A Dec, 2010 STRAWMAN LIMITED Revoked
EP03728969A Nov, 2010 Synthon B.V. Revoked
EP05722772A Sep, 2010 Gallafent, Antony Xavier Patent maintained as amended
EP05722772A Sep, 2010 APOTEX INC. Patent maintained as amended


Bristol Myers's Family Patents

Bristol Myers drugs have patent protection in a total of 61 countries. It's US patent count contributes only to 21.7% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Bristol Myers Drug List

Given below is the complete list of Bristol Myers's drugs and the patents protecting them.


1. Abraxane

Abraxane is protected by 32 patents, out of which 18 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9511046
(Pediatric)
Methods of treating pancreatic cancer 12 Jul, 2034
(8 years from now)
Active
US9511046 Methods of treating pancreatic cancer 12 Jan, 2034
(8 years from now)
Active
US9393318
(Pediatric)
Methods of treating cancer 04 Sep, 2032
(6 years from now)
Active
US9597409
(Pediatric)
Methods of treating cancer 04 Sep, 2032
(6 years from now)
Active
US9393318 Methods of treating cancer 04 Mar, 2032
(6 years from now)
Active
US9597409 Methods of treating cancer 04 Mar, 2032
(6 years from now)
Active
US8034375
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 13 Feb, 2027
(1 year, 1 month from now)
Active
US7758891
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
(7 months from now)
Active
US8268348
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
(7 months from now)
Active
US9101543
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
(7 months from now)
Active
US8034375 Combinations and modes of administration of therapeutic agents and combination therapy 13 Aug, 2026
(6 months from now)
Active
US7758891 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
(a month from now)
Active
US8268348 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
(a month from now)
Active
US9101543 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
(a month from now)
Active
US7820788
(Pediatric)
Compositions and methods of delivery of pharmacological agents 27 Apr, 2025
(8 months ago)
Expired
US7820788 Compositions and methods of delivery of pharmacological agents 27 Oct, 2024
(1 year, 2 months ago)
Expired
US7923536
(Pediatric)
Compositions and methods of delivery of pharmacological agents 09 Jun, 2024
(1 year, 7 months ago)
Expired
US8138229
(Pediatric)
Compositions and methods of delivery of pharmacological agents 09 Jun, 2024
(1 year, 7 months ago)
Expired
US8314156
(Pediatric)
Compositions and methods of delivery of pharmacological agents 09 Jun, 2024
(1 year, 7 months ago)
Expired
US7923536 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023
(2 years ago)
Expired
US8138229 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023
(2 years ago)
Expired
US8314156 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023
(2 years ago)
Expired
US8853260
(Pediatric)
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Apr, 2021
(4 years ago)
Expired
US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Oct, 2020
(5 years ago)
Expired
USRE41884 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions 14 Aug, 2016
(9 years ago)
Expired
US5498421 Composition useful for in vivo delivery of biologics and methods employing same 12 Mar, 2013
(12 years ago)
Expired
US5439686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor 22 Feb, 2013
(12 years ago)
Expired
US6096331 Methods and compositions useful for administration of chemotherapeutic agents 22 Feb, 2013
(12 years ago)
Expired
US6506405 Methods and formulations of cremophor-free taxanes 22 Feb, 2013
(12 years ago)
Expired
US6537579 Compositions and methods for administration of pharmacologically active compounds 22 Feb, 2013
(12 years ago)
Expired
US6749868 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 22 Feb, 2013
(12 years ago)
Expired
US6753006 Paclitaxel-containing formulations 22 Feb, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abraxane's drug page


2. Baraclude

Baraclude is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5206244
(Pediatric)
Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Aug, 2015
(10 years ago)
Expired
US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Feb, 2015
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baraclude's drug page


3. Cobenfy

Cobenfy is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10925832 Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
(13 years from now)
Active
US10933020 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
(13 years from now)
Active
US11452692 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
(13 years from now)
Active
US11471413 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
(13 years from now)
Active
US11890378 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation 27 Sep, 2039
(13 years from now)
Active
US10238643 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
(4 years from now)
Active
US10265311 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
(4 years from now)
Active
US10369143 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
(4 years from now)
Active
US10369144 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
(4 years from now)
Active
US10695339 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation 21 Jul, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cobenfy's drug page


4. Daklinza

Daklinza is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8629171 Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt 13 Jun, 2031
(5 years from now)
Active
US8329159 Hepatitis C virus inhibitors 24 Jul, 2029
(3 years from now)
Active
US8642025 Hepatitis C virus inhibitors 11 Aug, 2027
(1 year, 6 months from now)
Active
US8900566 Hepatitis C virus inhibitors 08 Aug, 2027
(1 year, 6 months from now)
Active
US9421192 Hepatitis C virus inhibitors 08 Aug, 2027
(1 year, 6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daklinza's drug page


5. Eliquis

Eliquis is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9326945
(Pediatric)
Apixaban formulations 24 Aug, 2031
(5 years from now)
Active
US9326945 Apixaban formulations 24 Feb, 2031
(5 years from now)
Active
US6967208
(Pediatric)
Lactam-containing compounds and derivatives thereof as factor Xa inhibitors 21 May, 2027
(1 year, 4 months from now)
Active
US6967208 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors 21 Nov, 2026
(10 months from now)
Active
US6413980 Nitrogen containing heterobicycles as factor Xa inhibitors 22 Dec, 2019
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eliquis's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Glucovance

Glucovance is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6303146
(Pediatric)
Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jan, 2020
(5 years ago)
Expired
US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jul, 2019
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucovance's drug page


7. Idhifa

Idhifa is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9732062 Therapeutically active compounds and their methods of use 16 Sep, 2034
(8 years from now)
Active
US10093654 Therapeutically active compounds and their methods of use 01 Aug, 2034
(8 years from now)
Active
US9738625 Therapeutically active compounds and their methods of use 01 Aug, 2034
(8 years from now)
Active
US10294215 Therapeutically active compounds and their methods of use 07 Jan, 2033
(6 years from now)
Active
US9512107 Therapeutically active compositions and their methods of use 07 Jan, 2033
(6 years from now)
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Idhifa's drug page


8. Inrebic

Inrebic is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11400092 Methods of treating myeloproliferative disorders 24 Sep, 2039
(13 years from now)
Active
US10391094 Compositions and methods for treating myelofibrosis 04 Jun, 2032
(6 years from now)
Active
US7528143 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Nov, 2031
(5 years from now)
Active
US8138199 Use of bi-aryl meta-pyrimidine inhibitors of kinases 30 Jun, 2028
(2 years from now)
Active
US7825246 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Dec, 2026
(11 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inrebic's drug page


9. Istodax

Istodax is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7608280 Method of producing FR901228 22 Aug, 2021
(4 years ago)
Expired
US7611724 Method of producing FR901228 22 Aug, 2021
(4 years ago)
Expired
US4977138 FR901228 substance and preparation thereof 22 Aug, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Istodax's drug page


10. Pravachol

Pravachol is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5622985
(Pediatric)
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Oct, 2014
(11 years ago)
Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Apr, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pravachol's drug page


11. Pravigard Pac (copackaged)

Pravigard Pac (copackaged) is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5622985
(Pediatric)
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Oct, 2014
(11 years ago)
Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Apr, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pravigard Pac (copackaged)'s drug page


12. Revlimid

Revlimid is protected by 30 patents, out of which 28 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8741929 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas 08 Mar, 2028
(2 years from now)
Active
US7465800 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 27 Apr, 2027
(1 year, 3 months from now)
Active
US7855217 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 24 Nov, 2024
(1 year, 1 month ago)
Expired
US7468363 Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023
(2 years ago)
Expired
US7968569 Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023
(2 years ago)
Expired
US8492406 Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023
(2 years ago)
Expired
US8530498 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione 15 May, 2023
(2 years ago)
Expired
US8648095 Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor 15 May, 2023
(2 years ago)
Expired
US9101621 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation 15 May, 2023
(2 years ago)
Expired
US9101622 Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone 15 May, 2023
(2 years ago)
Expired
US9155730 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023
(2 years ago)
Expired
US9393238 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023
(2 years ago)
Expired
US7189740 Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes 11 Apr, 2023
(2 years ago)
Expired
US8404717 Methods of treating myelodysplastic syndromes using lenalidomide 11 Apr, 2023
(2 years ago)
Expired
US9056120 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine 11 Apr, 2023
(2 years ago)
Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020
(5 years ago)
Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US5635517 Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines 04 Oct, 2019
(6 years ago)
Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US6281230 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016
(9 years ago)
Expired
US6555554 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016
(9 years ago)
Expired
US7119106 Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline 24 Jul, 2016
(9 years ago)
Expired
US8288415 Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione 24 Jul, 2016
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Revlimid's drug page


13. Reyataz

Reyataz is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6087383
(Pediatric)
Bisulfate salt of HIV protease inhibitor 21 Jun, 2019
(6 years ago)
Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Dec, 2018
(7 years ago)
Expired
US5849911
(Pediatric)
Antivirally active heterocyclic azahexane derivatives 20 Dec, 2017
(8 years ago)
Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Jun, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyataz's drug page


14. Sprycel

Sprycel is protected by 10 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7491725
(Pediatric)
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Sep, 2026
(8 months from now)
Active
US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Mar, 2026
(2 months from now)
Active
US8680103
(Pediatric)
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Aug, 2025
(5 months ago)
Expired
US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Feb, 2025
(11 months ago)
Expired
US6596746
(Pediatric)
Cyclic protein tyrosine kinase inhibitors 28 Dec, 2020
(5 years ago)
Expired
US7153856
(Pediatric)
Cyclic protein tyrosine kinase inhibitors 28 Oct, 2020
(5 years ago)
Expired
US7125875
(Pediatric)
Cyclic protein tyrosine kinase inhibitors 13 Oct, 2020
(5 years ago)
Expired
US6596746 Cyclic protein tyrosine kinase inhibitors 28 Jun, 2020
(5 years ago)
Expired
US7153856 Cyclic protein tyrosine kinase inhibitors 28 Apr, 2020
(5 years ago)
Expired
US7125875 Cyclic protein tyrosine kinase inhibitors 13 Apr, 2020
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sprycel's drug page


15. Sustiva

Sustiva is protected by 13 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6238695
(Pediatric)
Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019
(6 years ago)
Expired
US6555133
(Pediatric)
Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019
(6 years ago)
Expired
US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019
(6 years ago)
Expired
US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019
(6 years ago)
Expired
US6639071
(Pediatric)
Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Aug, 2018
(7 years ago)
Expired
US6939964
(Pediatric)
Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jul, 2018
(7 years ago)
Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Feb, 2018
(7 years ago)
Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jan, 2018
(7 years ago)
Expired
US5663169
(Pediatric)
Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Mar, 2015
(10 years ago)
Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Sep, 2014
(11 years ago)
Expired
US5519021
(Pediatric)
Benzoxazinones as inhibitors of HIV reverse transcriptase 21 Nov, 2013
(12 years ago)
Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 May, 2013
(12 years ago)
Expired
US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase 07 Aug, 2012
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sustiva's drug page


16. Thalomid

Thalomid is protected by 20 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7230012 Pharmaceutical compositions and dosage forms of thalidomide 09 Dec, 2023
(2 years ago)
Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020
(5 years ago)
Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US6869399 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US7141018 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US7959566 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(5 years ago)
Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US7874984 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(7 years ago)
Expired
US7435745 Methods and compositions for inhibition of angiogenesis 03 Nov, 2017
(8 years ago)
Expired
US5629327 Methods and compositions for inhibition of angiogenesis 13 May, 2014
(11 years ago)
Expired
US6235756 Methods and compositions for inhibition of angiogenesis by thalidomide 01 Mar, 2013
(12 years ago)
Expired
US7723361 Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide 01 Mar, 2013
(12 years ago)
Expired
US8143283 Methods for treating blood-born tumors with thalidomide 01 Mar, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Thalomid's drug page


17. Zerit Xr

Zerit Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7135465
(Pediatric)
Sustained release beadlets containing stavudine 18 Aug, 2023
(2 years ago)
Expired
US7135465 Sustained release beadlets containing stavudine 18 Feb, 2023
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zerit Xr's drug page